NCT04527081View on ClinicalTrials.gov

Study of COVID-19 DNA Vaccine (AG0302-COVID19)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

November 9, 2020

Study Completion Date

September 24, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

AG0302-COVID19

2.0 mg of AG0302-COVID19 twice at 2-week intervals

BIOLOGICAL

AG0302-COVID19

2.0 mg of AG0302-COVID19 twice at 4-week intervals

BIOLOGICAL

AG0302-COVID19

2.0 mg of AG0302-COVID19 three times at 2-week intervals

Trial Locations (1)

Unknown

Osaka University Hospital, Osaka

All Listed Sponsors
lead

AnGes, Inc.

INDUSTRY

NCT04527081 - Study of COVID-19 DNA Vaccine (AG0302-COVID19) | Biotech Hunter | Biotech Hunter